DBV Technologies, a France-headquartered clinical-stage specialist biopharmaceutical company with a US office in New York, has welcomed Edward Jordan as Senior Vice President, Commercial Operations North America.
The firm is preparing for the commercialisation of its two leading product candidates for treating food allergies, Viaskin Peanut and Viaskin Milk.
Jordan has brought to DBV more than 20 years of commercial leadership and product launch experience in both prescription and over-the-counter (OTC) products.
Prior to joining DBV, he was SVP, Commercial Operations at AMAG Pharmaceuticals. In an earlier role he was Head of Sales, Marketing, Training & Effectiveness, Women's Health Care at Teva Pharmaceuticals.
Earlier in his career, Jordan held a series of global development and leadership roles for the pharmaceutical business at Schering-Plough Corporation (now Merck). In 17 years at Schering-Plough he gained extensive allergy experience with multiple products at varying stages in their lifecycles. As Senior Director of International Operations, he engineered enhancements to financial planning, promotional strategies, product launches and operational effectiveness.
